Multiple Sclerosis Patients See Improvement with Vaporized Cannabis Cannabinoids THC and CBD

Image | adode.stock/Vitalii Vodolazskyi

A recent study published in the Journal of Clinical Medicine investigated vaporized cannabis’s use in patients with multiple sclerosis (MS), which contain standardized percentages of tetrahydrocannabinol (THC) and cannabidiol (CBD) (1).

Researchers in Greece analyzed vaporized cannabis consisting of 13% CBD and 9% THC (1), with 69 participants. Some of the MS participants were experiencing muscle spasticity, disability progression rate, and bladder dysfunction. These symptoms were measured at baseline and then again at three months and six months.

“Significant improvement was observed across all outcome assessments”, researchers commented (1,2).

“This study represents an initial step toward understanding the real-world application of vaporized THC: CBD formulations in MS management,” the study’s authors said (1,2). “The findings … highlight the potential benefits of CBD 13 [percent] | THC 9 [percent] vaporized formulations in managing MS symptoms, particularly when integrated into the existing treatment framework of DMTs [disease modifying therapies] and other MS symptomatic therapies.”

“This study explored the potential role of a CBD13/THC9 vaporized formulation as a complementary approach for managing MS-related muscle spasticity and bladder dysfunction. Statistically significant improvements were observed in these symptoms over six months; yet the magnitude of change was modest in some measures. The observed correlations between higher CBD13/THC9 doses and slight reductions in disability levels, as well as patterns related to smoking status and adverse effects, suggest that individual responses to treatment may vary,” researchers commented in the study (2).

Researchers witnessed significant improvements in MS symptoms over the course of six months but did mention that suggest that “individual responses to treatment may vary,” and that the results should be “interpreted with caution,” (2). Further research will be needed to continue investigating vaporized cannabis’s impact on MS. Researchers mentioned (2), “Despite these limitations, this study represents an initial step toward understanding the real-world application of vaporized THC:CBD formulations in MS management, emphasizing the need for further research to refine treatment approaches that balance therapeutic benefits with potential risks.”

References

1. Norml. Vaporized cannabis provides “significant improvements” for ms patients https://norml.org/news/2025/04/03/study-vaporized-cannabis-provides-significant-improvements-for-multiple-sclerosis-patients/ (accessed Apr 4, 2025).
2. Stavrogianni, K.; Kitsos, D.K.; Giannopapas, V.; Smyrni, V.; Chasiotis, A.K.; Akrivaki, A.; Dimitriadou, E.-M.; Zompola, C.; Tzartos, J.S.; Tsivgoulis, G.; et al. Evaluating Vaporized Cannabinoid Therapy in Multiple Sclerosis: Findings from a Prospective Single-Center Clinical Study. J. Clin. Med. 2025, 14, 2121. https://doi.org/10.3390/jcm14062121